IL111670A - Isoxazoline compounds and antiinflammatory pharmaceutical compositions containing them - Google Patents

Isoxazoline compounds and antiinflammatory pharmaceutical compositions containing them

Info

Publication number
IL111670A
IL111670A IL11167094A IL11167094A IL111670A IL 111670 A IL111670 A IL 111670A IL 11167094 A IL11167094 A IL 11167094A IL 11167094 A IL11167094 A IL 11167094A IL 111670 A IL111670 A IL 111670A
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
carbons
alkyl
acceptable salt
compound according
Prior art date
Application number
IL11167094A
Other languages
English (en)
Other versions
IL111670A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL111670A0 publication Critical patent/IL111670A0/xx
Publication of IL111670A publication Critical patent/IL111670A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL11167094A 1993-11-26 1994-11-17 Isoxazoline compounds and antiinflammatory pharmaceutical compositions containing them IL111670A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15724893A 1993-11-26 1993-11-26
US26208694A 1994-06-17 1994-06-17

Publications (2)

Publication Number Publication Date
IL111670A0 IL111670A0 (en) 1995-01-24
IL111670A true IL111670A (en) 1998-08-16

Family

ID=26853945

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11167094A IL111670A (en) 1993-11-26 1994-11-17 Isoxazoline compounds and antiinflammatory pharmaceutical compositions containing them

Country Status (24)

Country Link
US (1) US5716967A (cs)
EP (1) EP0730588B1 (cs)
JP (1) JP2802547B2 (cs)
KR (1) KR0182324B1 (cs)
CN (1) CN1046274C (cs)
AT (1) ATE154932T1 (cs)
AU (1) AU687452B2 (cs)
BR (1) BR9408174A (cs)
CA (1) CA2176255C (cs)
CO (1) CO4180606A1 (cs)
CZ (1) CZ283564B6 (cs)
DE (1) DE69404044T2 (cs)
DK (1) DK0730588T3 (cs)
EG (1) EG20693A (cs)
ES (1) ES2104424T3 (cs)
FI (1) FI945557L (cs)
GR (1) GR3024133T3 (cs)
HU (1) HUT76784A (cs)
IL (1) IL111670A (cs)
NO (1) NO962127D0 (cs)
NZ (1) NZ274244A (cs)
PE (1) PE33495A1 (cs)
PL (1) PL314605A1 (cs)
WO (1) WO1995014681A1 (cs)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
CA2185019C (en) * 1994-03-09 2000-08-08 Pfizer Limited Isoxazoline compounds as inhibitors of tnf release
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
IL147688A0 (en) 1999-08-21 2002-08-14 Byk Gulden Lomberg Chem Fab Synergistic combination
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor
KR100399361B1 (ko) 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
DE19953024A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS PROMOTING THE GUISON OF A BONE FRACTURE
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
NZ529654A (en) * 2001-05-29 2005-12-23 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
CA2450589C (en) 2001-06-08 2011-12-20 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US7125870B2 (en) * 2002-11-06 2006-10-24 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
HRP20141241T1 (hr) 2004-03-05 2015-02-13 Nissan Chemical Industries, Ltd. Spoj benzamida supstituiran izoksazolinom i sredstvo za suzbijanje štetnih organizama
WO2005094329A2 (en) * 2004-03-26 2005-10-13 Cytokine Pharmasciences, Inc. Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ES2370788T3 (es) * 2005-02-07 2011-12-22 Aerocrine Ab Controlar flujo de aliento exhalado durante análisis.
CN101217953A (zh) * 2005-03-15 2008-07-09 加尼亚尔免疫治疗公司 具有免疫调节活性的化合物
AU2006239221C1 (en) 2005-04-28 2012-08-16 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
EP1879884B1 (en) * 2005-05-03 2010-08-25 Ranbaxy Laboratories Limited Azole-based phosphodiesterase inhibitors
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN104208718B (zh) 2009-02-20 2017-12-29 2-Bbb医疗股份有限公司 基于谷胱甘肽的药物递送系统
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
IL295075A (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
JP5968999B2 (ja) 2011-03-31 2016-08-10 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草剤としておよび殺菌剤として活性な３−フェニルイソオキサゾリン−５−カルボキサミドおよび３−フェニルイソオキサゾリン−５−チオアミド
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2854805B1 (en) 2012-04-17 2019-06-12 GeneOne Life Science Inc. Compounds having immunomodulator activity
EP2900645B1 (de) * 2012-09-25 2019-08-21 Bayer CropScience AG Herbizid wirksame 3-phenylisoxazolinderivate
EP2925721B1 (en) * 2012-11-20 2017-06-07 Biogen MA Inc. S1p and/or atx modulating agents
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN103381157A (zh) * 2013-07-04 2013-11-06 丁圣雨 Chukrasone B在治疗慢性阻塞性肺疾病的药物中的应用
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
CN106573924B (zh) * 2014-04-22 2019-06-25 诺华股份有限公司 作为LpxC抑制剂的异噁唑啉异羟肟酸衍生物
EA202090018A1 (ru) 2017-06-13 2020-05-26 Байер Акциенгезельшафт Гербицидно-активные 3-фенилизоксазолин-5-карбоксамиды тетрагидро- и дигидрофурановых карбоксамидов
EP3638665B1 (de) 2017-06-13 2021-07-21 Bayer Aktiengesellschaft Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von tetrahydro- und dihydrofurancarbonsäuren und -estern
CN111164077B (zh) 2017-08-17 2023-12-19 拜耳公司 除草活性的环戊基羧酸和其酯的3-苯基-5-三氟甲基异噁唑啉-5-甲酰胺
BR112020015096A2 (pt) 2018-01-25 2020-12-08 Bayer Aktiengesellschaft 3-fenilisoxazolina-5-carboxamidas herbicidamente ativas de derivados de ácido ciclopentenilcarboxílico
PL3937637T3 (pl) 2019-03-12 2023-08-07 Bayer Aktiengesellschaft Herbicydowo czynne 3-fenyloizoksazolino-5-karboksyamidy estrów kwasów cyklopentenylokarboksylowych zawierających S
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55104273A (en) * 1979-02-05 1980-08-09 Sankyo Co Ltd 4-phenylisoxazole derivative and its preparation
JPS62103070A (ja) * 1985-10-29 1987-05-13 Mitsui Toatsu Chem Inc イソオキサゾリン誘導体および植物生長調節剤
US4861798A (en) * 1986-12-29 1989-08-29 Bristol-Myers Company Lipoxygenase inhibitory compounds
US4731382A (en) * 1986-12-29 1988-03-15 Bristol-Myers Company Lipoxygenase inhibitory phenylalkanohydroxamic acids
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
IL92915A0 (en) * 1989-01-05 1990-09-17 Ciba Geigy Ag Certain pyrrolylphenyl-substituted hydroxamic acid derivatives
DE3939010A1 (de) * 1989-11-25 1991-05-29 Hoechst Ag Isoxazoline, verfahren zu ihrer herstellung und ihre verwendung als pflanzenschuetzende mittel
JP2787602B2 (ja) * 1990-01-24 1998-08-20 大鵬薬品工業株式会社 イソキサゾリン誘導体
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5140047A (en) * 1991-05-03 1992-08-18 Smithkline Beecham Corporation Lipoxygenase inhibitors
GB9215921D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
WO1994018158A1 (en) * 1993-02-15 1994-08-18 Pfizer Inc. Spiroalkylhydroxyureas for use as lipoxygenase inhibitors

Also Published As

Publication number Publication date
CN1136314A (zh) 1996-11-20
BR9408174A (pt) 1997-05-27
NO962127L (no) 1996-05-24
KR0182324B1 (ko) 1999-05-01
CZ151096A3 (en) 1997-01-15
AU687452B2 (en) 1998-02-26
PL314605A1 (en) 1996-09-16
EG20693A (en) 1999-11-30
WO1995014681A1 (en) 1995-06-01
DK0730588T3 (da) 1997-12-08
PE33495A1 (es) 1995-10-27
ES2104424T3 (es) 1997-10-01
NO962127D0 (no) 1996-05-24
US5716967A (en) 1998-02-10
FI945557A7 (fi) 1995-05-27
AU7821894A (en) 1995-06-13
ATE154932T1 (de) 1997-07-15
IL111670A0 (en) 1995-01-24
CA2176255A1 (en) 1995-06-01
DE69404044T2 (de) 1997-10-16
EP0730588B1 (en) 1997-07-02
NZ274244A (en) 1997-09-22
DE69404044D1 (de) 1997-08-07
EP0730588A1 (en) 1996-09-11
CO4180606A1 (es) 1995-06-07
CA2176255C (en) 1999-02-23
FI945557A0 (fi) 1994-11-25
CZ283564B6 (cs) 1998-05-13
JP2802547B2 (ja) 1998-09-24
JPH09500147A (ja) 1997-01-07
GR3024133T3 (en) 1997-10-31
KR960705795A (ko) 1996-11-08
HU9601412D0 (en) 1996-07-29
HUT76784A (en) 1997-11-28
CN1046274C (zh) 1999-11-10
FI945557L (fi) 1995-05-27

Similar Documents

Publication Publication Date Title
AU687452B2 (en) Isoxazoline compounds as antiinflammatory agents
AU684887B2 (en) Isoxazoline compounds as inhibitors of TNF release
EP0730587B1 (en) 3-phenyl-2-isoxazolines as antiinflammatory agents
AU728329B2 (en) New substituted biphenyl or phenylpyridine compounds, a process for their preparation and pharmaceutical compositions containing them
US8748466B2 (en) Isoxazole derivatives useful as antibacterial agents
US5326770A (en) Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
JPH08504435A (ja) タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
BRPI0613943A2 (pt) composto, composição farmacêutica, enantiÈmeros (+) e (-) isolados de um composto, método para produzir um composto, composição neurobiologicamente ativa, usos de um composto, de uma composição farmacêutica, e de uma composiçãoneurobiologicamente ativa
JP7381578B2 (ja) ヒストンデアセチラーゼの二環式阻害剤
EP2161997A1 (en) Tricyclic inhibitors of fatty acid amide hydrolase
CA2721576A1 (en) Compound having npy y5 receptor antagonist activity
JP2005501800A (ja) ジヒドロピラゾロピリジン化合物およびその医薬用途
JP2008508335A (ja) Ｍａｏｂインヒビターとしてのベンジルオキシ誘導体
WO2012104538A1 (fr) Nouveaux dérivés de 1, 5 - dihydropyrrol - 2 - one utiles pour le traitement paludisme ou d'autres maladies parasitaires et fongiques
HK1194368A (en) Isoxazole derivatives useful as antibacterial agents

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees